{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:16:41Z","timestamp":1777652201460,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacadv.2025.102498","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:33:40Z","timestamp":1767335620000},"page":"102498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Residual Cardiovascular Biomarkers After Medical Therapy and Their Prognostic Implications Following Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"5","author":[{"given":"Jun Hwan","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Gyu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seok","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2920-7411","authenticated-orcid":false,"given":"Jin-Sin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Ki","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-3726","authenticated-orcid":false,"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.102498_bib1","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2018.09.052","article-title":"Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review","volume":"72","author":"Gallone","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib9","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib12","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2014.07.017","volume":"64","author":"Fihn","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib14","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib15","first-page":"3235","article-title":"ESC\/EACTS myocardial revascularization guidelines 2014","volume":"35","author":"Kolh","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2012.03.022","article-title":"Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies","volume":"164","author":"Jeong","year":"2012","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.jacadv.2025.102498_bib18","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib20","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102498_bib21","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/qjmed\/hcg129","article-title":"Fibrinogen: biochemistry, epidemiology and determinants","volume":"96","author":"Kamath","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jacadv.2025.102498_bib23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2025.102498_bib24","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102498_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacasi.2021.11.014","article-title":"Residual inflammatory risk and its association with events in East Asian patients after coronary intervention","volume":"2","author":"Ahn","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacadv.2025.102498_bib26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib27","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month dual antiplatelet therapy followed by clopidogrel vs 12-Month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.102498_bib28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102498_bib29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4070\/kcj.2020.0287","article-title":"Another unmet need against residual risk of atherosclerotic cardiovascular disease: can \"Thrombin Pathway\" be a new target for therapy?","volume":"50","author":"Kim","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacadv.2025.102498_bib30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib31","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","article-title":"Fibrinogen and risk of cardiovascular disease. The framingham study","volume":"258","author":"Kannel","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.102498_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(86)90111-X","article-title":"Haemostatic function and ischaemic heart disease: principal results of the Northwick park heart study","volume":"2","author":"Meade","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102498_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","article-title":"Fibrinogen as a key regulator of inflammation in disease","volume":"34","author":"Davalos","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jacadv.2025.102498_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbrc.2009.10.082","article-title":"Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: pro-inflammatory effect on atherosclerosis","volume":"390","author":"Guo","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacadv.2025.102498_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2025.102498_bib36","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/eurheartj\/ehae296","article-title":"Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions","volume":"45","author":"Kwon","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.102498_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jacadv.2025.102498_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib39","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.102498_bib40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102498_bib41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102498_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-14-1061","article-title":"Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the rotterdam study","volume":"173","author":"de Keyser","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jacadv.2025.102498_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00441-012-1437-1","article-title":"Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis","volume":"349","author":"Stancu","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jacadv.2025.102498_bib44","first-page":"978","article-title":"Revisiting the lipid paradox in ST-elevation myocardial infarction in the Chinese population: findings from the CCC-ACS project","volume":"10","author":"Sun","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacadv.2025.102498_bib45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.amjcard.2014.12.006","article-title":"Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox)","volume":"115","author":"Reddy","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.102498_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025958","article-title":"Impact of low baseline low-density lipoprotein cholesterol on long-term postdischarge cardiovascular outcomes in patients with acute myocardial infarction","volume":"11","author":"Cho","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25009275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25009275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:50:58Z","timestamp":1772509858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25009275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2772963X25009275"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102498","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual Cardiovascular Biomarkers After Medical Therapy and Their Prognostic Implications Following Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102498"}}